Azelaic Acid 15% Gel + Inactive 15% gel base
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Seborrheic Dermatitis on the Face
Conditions
Seborrheic Dermatitis on the Face
Trial Timeline
Dec 1, 2006 → Mar 1, 2007
NCT ID
NCT00408330About Azelaic Acid 15% Gel + Inactive 15% gel base
Azelaic Acid 15% Gel + Inactive 15% gel base is a phase 2 stage product being developed by Bayer for Seborrheic Dermatitis on the Face. The current trial status is completed. This product is registered under clinical trial identifier NCT00408330. Target conditions include Seborrheic Dermatitis on the Face.
What happened to similar drugs?
2 of 6 similar drugs in Seborrheic Dermatitis on the Face were approved
Approved (2) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00408330 | Phase 2 | Completed |
Competing Products
15 competing products in Seborrheic Dermatitis on the Face
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elidel + Ketoconazole Cream | Novartis | Phase 2 | 35 |
| PF-07038124 + Placebo Ointment | Pfizer | Phase 2 | 27 |
| Ketoconazole | GSK plc | Approved | 43 |
| Ruxolitinib 1.5% Cream | Incyte | Phase 2 | 32 |
| Roflumilast Foam 0.3% + Vehicle foam | Arcutis Biotherapeutics | Phase 2 | 29 |
| Roflumilast Foam + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 34 |
| ARQ-154 | Arcutis Biotherapeutics | Phase 2 | 29 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 30 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 30 |
| A-101 Topical Solution | Aclaris Therapeutics | Approved | 33 |
| A-101 | Aclaris Therapeutics | Phase 2 | 25 |
| A-101 Solution | Aclaris Therapeutics | Phase 3 | 30 |
| A-101 | Aclaris Therapeutics | Phase 2 | 25 |
| A-101 25% + A-101 32.5% + A-101 40% + A-101 Vehicle | Aclaris Therapeutics | Phase 1/2 | 22 |
| A-101 Vehicle + A-101 (40) Topical Solution + A-101 (32.5) Topical Solution | Aclaris Therapeutics | Phase 2 | 25 |